HEB - Hemispherx Biopharma, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
0.1407
+0.0007 (+0.50%)
As of 9:44AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1400
Open0.1450
Bid0.1406 x 3200
Ask0.1430 x 3000
Day's Range0.1407 - 0.1452
52 Week Range0.1300 - 0.3500
Volume95,645
Avg. Volume1,148,779
Market Cap9.065M
Beta (3Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-0.2220
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.65
Trade prices are not sourced from all markets
  • GlobeNewswire1 hour ago

    Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019

    Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today that CEO Thomas K. Equels will present at the Planet MicroCap Showcase on Wednesday, May 1, 2019, at 8:30 a.m. PT. Equels' presentation will focus on the company’s ongoing clinical trials and programs using its flagship investigational drug Ampligen to treat multiple cancer types. The company recently announced significant progress in its Ampligen pancreatic cancer program and multiple Ampligen plus checkpoint blockade immuno-oncology programs.

  • ACCESSWIRE2 days ago

    MicroCap Review Magazine Spring 2019 Issue Now Available

    The Digital Issue of the Spring 2019 MicroCap Review Magazine,The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / April 23, 2019 / SNN ...

  • GlobeNewswire3 days ago

    Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer

    OCALA, Fla., April 22, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced the appointment of Ellen Lintal as the company’s new Chief Accounting Officer. Lintal joined Hemispherx in 2018 as VP of Finance & Control. “Ms. Lintal has done a superb job since arriving at Hemispherx and will make an excellent Chief Accounting Officer,” said CEO Thomas K. Equels.

  • Some Hemispherx Biopharma (NYSEMKT:HEB) Shareholders Have Copped A 96% Share Price Wipe Out
    Simply Wall St.12 days ago

    Some Hemispherx Biopharma (NYSEMKT:HEB) Shareholders Have Copped A 96% Share Price Wipe Out

    Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish catastrophic capital loss on anyone. For example, we sympathize with anyone who was caught holding Hemispherx Biop...

  • GlobeNewswire23 days ago

    Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab

    OCALA, Fla., April 02, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell Park) in Buffalo, N.Y. evaluating Hemispherx’ experimental drug Ampligen® (rintatolimod), a dsRNA TLR3 agonist, in combination with Merck’s Keytruda® (pembrolizumab), an anti-PD-1 check-point blockade therapy, in the treatment of metastatic triple-negative breast cancer.

  • GlobeNewswire24 days ago

    Hemispherx Reports 2018 Year-end Financial Results

    OCALA, Fla., April 01, 2019 -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces financial results for the fiscal year ended December 31, 2018, and provides a business.

  • GlobeNewswirelast month

    Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs

    Hemispherx Biopharma Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D company focused on unmet medical needs in immunology, announced today the first of a series of planned quarterly press release updates highlighting the progress and achievement of milestones in the Company’s ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of existing cancer immunotherapy, such as checkpoint blockade therapies. The Company has recently refocused its efforts to concentrate on the use of Ampligen as an immuno-therapy based on preclinical and early clinical evidence supporting the drug candidate’s potential in the fight against cancer. “We believe steady progress in these combination therapy clinical trials will be an important driver for Hemispherx’s long-term success.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that the Company’s previously announced rights offering (the “Rights Offering”) expired on Tuesday, March 5, 2019 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $5.3 million in gross proceeds. The results of the Rights Offering and Hemispherx’s estimates regarding the aggregate gross proceeds of the Rights Offering to be received by Hemispherx are subject to finalization and verification by Hemispherx and its subscription agent.

  • GlobeNewswire2 months ago

    Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020

    OCALA, Fla., Feb. 28, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today the extension of its Early Access Program (EAP) at the Erasmus Medical Center in the Netherlands using its drug Ampligen in the treatment of pancreatic cancer. The EAP is approved by the Dutch Health Inspectorate until March 9, 2020 to treat pancreatic cancer patients diagnosed with any stage of the serious disease. Approximately 459,000 people globally with 55,000 in the U.S. are diagnosed each year with pancreatic cancer, and it causes approximately 430,000 deaths worldwide and 44,000 in the U.S. according to the Cancer Research Institute (https://www.cancerresearch.org/immunotherapy/cancer-types/pancreatic-cancer).

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that it has extended the initial rights offering subscription period until 5:00 PM Eastern time on March 5, 2019. If you would like to participate, the subscription period for the rights offering has commenced. If exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within the time period provided by such nominee.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering  

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that it has adjusted certain pricing information for its previously announced rights offering and all of the members of the Company’s senior management and Board of Directors are planning to participate in the rights offering, each member exercising a portion of his respective rights. The subscription period for the rights offering will still expire at 5:00 PM Eastern time on March 1, 2019, unless extended by the Company. The unit pricing remains $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock with a stated value of $1,000 (and immediately convertible into Hemispherx’s common stock) and warrants to purchase Hemispherx’s common stock.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that the subscription period for the rights offering has commenced. If exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within the time period provided by such nominee. The broker, dealer, bank or other nominee may establish a deadline before March 1, 2019, by which instructions to exercise subscription rights, along with the required subscription payment, must be received.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record

    Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today issued a reminder to stockholders that the record date of its proposed rights offering is Thursday, February 14, 2019. To be a stockholder of record on the record date, ownership of Hemispherx stock must occur by market close on Tuesday, February 12, 2019 to account for settlement. Under the proposed rights offering, Hemispherx will distribute to its holders of common stock and to holders of certain options and warrants as of February 14, 2019, at no charge, one non-transferable subscription right for each share of common stock held or deemed held on the record date.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck’s Keytruda in the Treatment of Recurrent Ovarian Cancer

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on unmet medical needs in immunology and oncology, announced today the start at the UPMC Hillman Cancer Center in Pittsburgh, PA of a new clinical study supported by Merck that will combine the company’s Ampligen with Merck’s Keytruda for the treatment of recurrent, platinum-sensitive, ovarian cancer. The study will enroll up to 45 participants and be conducted at UPMC, which is sponsoring the study, by Robert Edwards, MD, director of the Ovarian Cancer Program at UPMC Magee Womens Hospital.

  • GlobeNewswire3 months ago

    Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering

    A registration statement relating to the rights offering has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. The securities described below to be offered by exercising the rights distributed in the rights offering may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. If the SEC does not declare the registration statement effective by February 14, 2019, the rights offering will be delayed at least two months or may not proceed.

  • GlobeNewswire3 months ago

    Hemispherx Biopharma Shares CEO’s Presentation at the NobleConXV Conference

    OCALA, Fla., Jan. 31, 2019 -- (NYSE American: HEB) — Hemispherx Biopharma Inc. CEO Tom Equels this week provided investors at NobleConXV with an update on the company’s ongoing.

  • GlobeNewswire3 months ago

    Recent Analysis Shows The Chemours, Inter Parfums, Newmont Mining, Sanderson Farms, NGL Energy Partners LP, and Hemispherx BioPharma Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    REPEAT - Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference

    OCALA, Fla., Jan. 24, 2019 -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs.

  • GlobeNewswire3 months ago

    Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference

    OCALA, Fla., Jan. 23, 2019 -- (NYSE American: HEB) — Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs.

  • GlobeNewswire4 months ago

    Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today Roswell Park Comprehensive Cancer Center Institutional Review Board (“IRB”) approval and shipment of Ampligen to start an oncology clinical study combining its dsRNA TLR3 agonist Ampligen with Merck’s Keytruda (pembrolizumab) in Metastatic Triple Negative Breast Cancer. The study will enroll at least six participants and be conducted by Drs. Mateusz Opyrchal and Pawel Kalinski at Roswell Park, a National Cancer Institute-designated comprehensive cancer center in Buffalo, New York.

  • GlobeNewswire4 months ago

    Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 325 recently manufactured vials of Ampligen to the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) clinical site at Incline Village, Nevada, run by Daniel Peterson, MD. The vials will be used in the Expanded Access Program (“EAP”) known as “AMP-511”. The FDA authorized the AMP-511 protocol to treat ME/CFS patients in an effort to expand compassionate care in the fight against this quality-of-life impacting disease where there is no commercially approved therapy.

  • GlobeNewswire4 months ago

    Hemispherx Biopharma Issues Business Update to Clarify Apple iOS12 Stocks Application ‘No Recent Stories’ Misinformation

    Hemispherx Biopharma, Inc. (NYSE American:HEB) continues to work with Apple and other affected parties for a solution to correct Apple iOS12 Stocks Application misinformation and enable investors using the Apple device for their market information to find current and accurate HEB recent stories and news. Hemispherx announced on December 12, 2018, that it had learned that the Apple iOS12 Stocks Application (“App”), as a result of a recent update, has a “glitch” affecting a large number of public companies, including Hemispherx. The defect results in an erroneous news message which inaccurately informs certain iPhone and Apple portable device users that there are “No Recent Stories” related to Hemispherx.

  • GlobeNewswire4 months ago

    Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program

    Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 720 vials of Ampligen to the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) clinical site at Hunter-Hopkins Center in Charlotte, N.C., where it will be used in the Expanded Access Program (”EAP”) known as “AMP-511”. The FDA authorized the AMP-511 protocol to treat ME/CFS patients in an effort to expand compassionate care in this dread disease which is estimated to disable more than 100,000 Americans. Hemispherx recently announced the expansion of the protocol, allowing new enrollees, who would not be eligible to participate in a future confirmatory trial.

  • GlobeNewswire4 months ago

    Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States

    Herbert Cousins, SVP for Patient Relations, and Peter Rodino III, Director of Governmental Relations, spoke with patients and the clinician about the company’s progress in expanding its U.S. Treatment Protocol/Expanded Access Program for ME/CFS, known as AMP-511. Hemispherx announced the expansion of the program in June — allowing new enrollees for the first time in more than a year — after completing its first commercial-sized lot of its pipeline drug Ampligen, producing ~8,500 vials.

  • GlobeNewswire4 months ago

    Hemispherx Biopharma Issues Letter to Stockholders

    OCALA, Fla., Dec. 12, 2018 -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announces that Thomas K. Equels, President and Chief Executive Officer, has issued a Letter to.